10V Stock Chart & Stats
€12.31
-€0.67(-5.16%)
At close: 4:00 PM EDT
€12.31
-€0.67(-5.16%)
Day’s Range― - ―
52-Week Range€4.36 - €13.51
Previous CloseN/A
Volume0.00
Average Volume (3M)33.00
Market Cap
€165.00M
Enterprise Value€148.31
Total Cash (Recent Filing)€186.63M
Total Debt (Recent Filing)€421.00K
Price to Earnings (P/E)―
Beta0.79
Next Earnings
Aug 06, 2026EPS Estimate
-1.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.98
Shares Outstanding13,621,483
10 Day Avg. Volume5
30 Day Avg. Volume33
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-1.25
Price to Sales (P/S)0.00
P/FCF Ratio-0.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€26.20Price Target Upside112.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-3.81
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Minimal DebtMinimal debt reduces fixed financial obligations and interest pressure, preserving flexibility to fund R&D and clinical programs through equity or partnerships. For a pre-revenue biotech, low leverage lowers bankruptcy risk and improves options for future financing or strategic deals over the next several quarters.
Positive Phase 2 CALLIPER DataRobust phase 2 signals on efficacy and a placebo-comparable safety profile materially increase the likelihood of successful late-stage programs. This supports advancement into confirmatory phase 3 trials and strengthens the drug's positioning as a differentiated oral MS therapy, improving long-term commercialization potential.
Experienced Commercial Leadership AddedBringing leaders with proven MS commercial and launch track records enhances the company's ability to design pivotal programs, engage regulators, and plan market entry. Such governance and operating experience materially improves execution odds from late-stage development to potential product launch and payer engagement.
Bears Say
Persistent Pre-revenue Cash BurnSustained negative operating and free cash flows require continual external financing until commercialization or partner revenue emerges. Ongoing burn pressures strategic flexibility, risks dilutive financing, and elevates execution risk if clinical timelines or regulatory paths extend beyond current runway.
Equity Volatility And Funding DependenceSharp swings in reported equity reflect sizable financing events and introduce trend uncertainty in the capital base. This volatility can complicate planning, impair investor confidence, and increase the likelihood of future equity raises at unfavorable terms, affecting long-term funding predictability.
Dilution Risk From Expanded Equity PlanA materially enlarged equity pool and ongoing option grants (including a 1,000,000 inducement grant to the CEO) indicate continued reliance on stock-based compensation. Over time this raises dilution risk for existing holders and can weaken per-share economics absent offsetting revenue or market-share gains.
Immunic News
10V FAQ
What was Immunic, Inc.’s price range in the past 12 months?
Immunic, Inc. lowest stock price was €4.36 and its highest was €13.51 in the past 12 months.
What is Immunic, Inc.’s market cap?
Immunic, Inc.’s market cap is €165.00M.
When is Immunic, Inc.’s upcoming earnings report date?
Immunic, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 2 days.
How were Immunic, Inc.’s earnings last quarter?
Immunic, Inc. released its earnings results on May 13, 2026. The company reported -€0.938 earnings per share for the quarter, missing the consensus estimate of -€0.598 by -€0.34.
Is Immunic, Inc. overvalued?
According to Wall Street analysts Immunic, Inc.’s price is currently Undervalued.
Does Immunic, Inc. pay dividends?
Immunic, Inc. does not currently pay dividends.
What is Immunic, Inc.’s EPS estimate?
Immunic, Inc.’s EPS estimate is -1.01.
How many shares outstanding does Immunic, Inc. have?
Immunic, Inc. has 13,621,483 shares outstanding.
What happened to Immunic, Inc.’s price movement after its last earnings report?
Immunic, Inc. reported an EPS of -€0.938 in its last earnings report, missing expectations of -€0.598. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Immunic, Inc.?
Currently, no hedge funds are holding shares in DE:10V
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immunic Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€26.20 (112.85% Upside)
€26.20 (112.85% Upside)
Blogger Sentiment
Bullish
DE:10V Sentiment 100%
Sector Average ―
Sector Average ―
Technicals
SMA
Positive
20 days / 200 days
Momentum
25.14%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
824.89%
Trailing 12-Months
Company Description
Immunic, Inc.
Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORγt, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.
10V Stock 12 Month Forecast
Average Price Target
€26.20
▲(112.85% Upside)
Technical Analysis
aTyr Pharma
―
vTv Therapeutics
―
NRX Pharmaceuticals
―
Equillium
―
Werewolf Therapeutics
―